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Extracellular matrixCollagenVI is a non-ﬁbrillar collagen present in the extracellularmatrix (ECM) as a complex polymer; themainly
expressed form is composed of α1, α2 and α3 chains; mutations in genes encoding these chains cause
myopathies known as Ullrich congenital muscular dystrophy (UCMD), Bethlem myopathy (BM) and
myosclerosis myopathy (MM). The collagen VI α6 chain is a recently identiﬁed component of the ECM of
the human skeletal muscle. Here we report that the α6 chain was dramatically reduced in skeletal muscle
and muscle cell cultures of genetically characterized UCMD, BM and MM patients, independently of the
clinical phenotype, the gene involved and the effect of the mutation on the expression of the “classical”
α1α2α3 heterotrimer. By contrast, the collagen VI α6 chain was normally expressed or increased in the
muscle of patients affected by other forms of muscular dystrophy, the overexpression matching with
areas of increased ﬁbrosis. In vitro treatment with TGF-β1, a potent collagen inducer, promoted the collagen
VI α6 chain deposition in the ECM of normal muscle cells, whereas, in cultures derived from collagen VI-related
myopathy patients, the collagen VI α6 chain failed to develop a network outside the cells and accumulated in
the endoplasmic reticulum. The defect of the α6 chain points to a contribution to the pathogenesis of collagen
VI-related disorders.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Collagen VI is an extracellular protein forming a distinct microﬁ-
brillar network in most interstitial connective tissues; it has a pivotal
role in maintaining skeletal muscle integrity and function [1,2]. In
humans, the most widespread collagen VI form is composed of α1,
α2 and α3 chains that associate inside the cell in a stoichiometric
ratio to form heterotrimeric monomers that assemble into dimers and
tetramers [3,4]. After secretion, tetramers associate end-to-end ﬁnally
forming microﬁbrils with a beaded ﬁlament structure [5] by interac-
tions of their non-collagenous domains [6]. In the extracellular matrix,
collagen VI interacts with several other components, including collagen
I [7], collagen II and decorin [8], collagen XIV [9], perlecan [10] and the
microﬁbril-associated glycoprotein MAGP1 [11].
Recently, three novel chains,α4,α5 andα6, were identiﬁed [12,13].
The new chains share sequence homology and domain structure witheletal Cell Biology, IOR, via di
5; fax: +39 051583593.
. This is an open access article underthe α3 chain; each of them consists of seven von Willebrand factor
type A (VWA) domains followed by a short collagenous domain, two
or three C-terminal VWA domains and a chain-speciﬁc domain [13].
Inmouse, the novel chains showa highly differential, often complemen-
tary expression [14], pointing to the possibility of tissue-speciﬁc roles of
the novel chains in collagen VI assembly and function. Due to their sim-
ilar structure and phylogenetic conservation, the new chains may have
the potential to replace the α3 chain forming α1α2α4, α1α2α5 and
α1α2α6 heterotrimers, thereby increasing the structural and functional
versatility of collagen VI [13]. This hypothesis is supported by results
obtained in the Col6a1−/−mousemodel inwhich all collagen VI chains
are largely absent, demonstrating that the presence of the collagen VI
α1 chain is a prerequisite for collagen VI secretion [14,15]. In contrast,
an in vitro study indicated that the α6 chain does not assemble with
α1 and α2 chains, pointing to an alternative collagen VI assembly
process [12,16].
In humans, the COL6A4 gene which encodes the α4 chain, is
inactivated because of a pericentric chromosomal inversion [13,17].
The expression of COL6A5mRNA is restricted to a few tissues, including
the lung, testis, colon [12] and skin [18]. The selective expression of thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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junction in the skeletal muscle [19], points to a specialized function
of α5 at junctional areas, perhaps important for the resistance to
tensile stress. COL6A6 mRNA is expressed in a wide range of fetal
and adult tissues [12]; in the skeletal muscle theα6 chain is localized
in the endomysium and perimysium, however, unlike the α3 chain,
it is not associated with basement membranes [19]. The differential
distribution of the novel chains points to speciﬁc roles in development,
tissue homeostasis or pathogenesis of inherited diseases.
Mutations in the COL6A1, COL6A2 and COL6A3 genes cause a
group of congenital muscular dystrophies: Ullrich congenital muscular
dystrophy (UCMD) is a severe disorder characterized by congenital
muscle weakness with axial and proximal joint contractures and
coexisting distal joint hypermobility [20]; Bethlem myopathy (BM) is
an autosomal dominant [21,22,23] or recessive [24] disorder character-
ized by slowly progressive axial and proximal muscle weakness with
ﬁnger ﬂexion contractures; myosclerosis myopathy (MM) is a recessive
disorder characterized by progressive all-joint contractures [25]. The
majority of collagen VI genemutations impair the secretion and deposi-
tion of collagen VI in skeletal muscle and/or ﬁbroblast cultures [26–28].
However, several dominant mutations in BM patients have no de-
tectable effect on collagen VI assembly and secretion, but compro-
mise protein function in the extracellular matrix of muscle [29].
We recently demonstrated that mutations in COL6A1 and COL6A2 im-
pair the expression ofα5 andα6 chains in the skin of UCMD patients,
pointing to a contribution of these chains to the skin phenotype. In
contrast, the α5 and α6 chains were apparently unaffected in the
skin of UCMD patients with COL6A3 mutations, suggesting that
they may compensate for the deﬁciency of the α3 chain by forming
α1α2α5 or α1α2α6 heterotrimers [18].
To give insights into the pathogenesis of collagen VI-related skeletal
muscle disease we explored the expression and distribution of the
newly identiﬁed α6 chain in muscle biopsies and muscle cell cultures
derived from patients affected by collagen VI-related myopathies.
2. Materials and methods
2.1. Patients and muscle biopsies
Skeletal muscle biopsies from three healthy subjects and sixteen
genetically characterized patients with collagen VI-related disease
(eight BM, seven UCMD and one MM patients) were collected
(Table 1). Muscle biopsies were also obtained from patients affected
by myopathies not related to collagen VI (one DMD, one MDC1A,
one Miyoshi myopathy, one EDMD, one rigid spine syndrome (RSS)
caused by FHL1, and one RSS caused by SEPN1). All samples were
frozen in melting isopentane and stored in liquid nitrogen. All pa-
tients were previously diagnosed by genetic, biochemical and/or
immunohistochemical analyses. All participants providedwritten in-
formed consent, and approval was obtained from the Ethics Committee
of the Rizzoli Orthopedic Institute.
2.2. Muscle cell cultures
Primary cell cultures derived from two normal controls, three dom-
inant BM, one recessive BM and two UCMD patients carryingmutations
in the COL6A1, COL6A2 or COL6A3 genes were established as described
[30] and maintained in DMEM plus 20% fetal calf serum [31]. Muscle
cells were grown until conﬂuence, treated with 0.25 mM L-ascorbic
acid (Sigma) and, when needed, supplemented with 10 ng/ml TGF-β1
(Sigma) for 96 h.
2.3. Immunoﬂuorescence and confocal microscopy
Frozen sections (7 μm-thick) from muscle of healthy donors and
dystrophic patients were ﬁxedwith 2% paraformaldehyde in phosphatebuffered saline (PBS), permeabilized with 0.15% Triton X100, incubated
with the afﬁnity-puriﬁed rabbit polyclonal antibody against the α6
chain [18], and detected with anti-rabbit TRITC-conjugated IgG
(DAKO). All sections were double labeled with a mouse monoclonal
antibody against the laminin γ1 chain (Chemicon) revealed with anti-
mouse FITC-conjugated IgG (DAKO). The expression and distribution
of classical collagen VI (α1α2α3) was assessed with a polyclonal
antibody (Fitzgerald Industries International) and compared with the
staining obtained with a rat monoclonal antibody against perlecan
(Chemicon), used as a basement membrane marker. Muscle cells
were grown on coverslips, ﬁxed with cold methanol, washed with PBS
and incubated with rabbit anti-α1α2α3 or anti-α6 chain antibodies.
Alpha-smooth muscle actin (α-SMA) expression was assessed in
cultured cells subjected to TGF-β1 treatment and compared to untreat-
ed cells by labeling with anti-α-SMA antibody (Sigma). All samples
were counterstained with DAPI to detect nuclei, mounted with an
anti-fading reagent (Molecular Probes) and observed with a Nikon
epiﬂuorescence microscope.
Double labelings with anti-Limp II (Santa Cruz Biotechnologies) or
anti-Grp78 (StressGene Biotechnologies) antibodies and the anti-α6
antibodywere performed after TGF-β1 treatment. The confocal imaging
was performed with an A1-R confocal laser scanning microscope
(Nikon), equipped with a Nikon 60×, 1.4 NA objective, and with
488 and 561 nm laser lines to excite FITC (green) and TRITC (red)
ﬂuorescence signals. Each ﬁnal confocal image, of 1024 × 1024 pixels
and 4096 gray levels, was obtained bymaximum intensity projection
of ten optical sections passed through the central region of the cells
(recorded at a z-step size of 300 nm).
2.4. Immunoblotting
Cultured cells were washed and scraped into lysis buffer (20 mM
Tris–HCl, pH 7.0, 1% Nonidet P-40, 150 mM NaCl, 10% glycerol, 10 mM
EDTA, 20 mM sodium ﬂuoride, 5 mM sodium pyrophosphate, 1 mM
Na3VO4, 1 mMphenylmethylsulfonyl ﬂuoride, and protease inhibitors).
The total protein content was quantiﬁed using a Bradford protein
assay (Bio-Rad). Samples (20 μg of protein) were reduced with 20%
β-mercaptoethanol and separated by SDS-PAGE on 4–20% gradient
polyacrylamide gels (Bio-Rad). The fractionated proteins were blot-
ted onto a nitrocellulose membrane at 30 V overnight at 4 °C and
themembrane was blockedwith 5% dry milk solution for subsequent
immunodetection with speciﬁc antibodies: anti-α6 chain was used
at 1:500; anti-α1 chain (Santa Cruz) at 1:1000; anti-collagen VI
(Fitzgerald) at 1:500, and anti-pSMAD 2/3 Ser 423/425 (Santa Cruz)
at 1:500. Loading controls were performed with an antibody against
GAPDH (Millipore), at 1:8000. Secondary antibodies conjugated
with horseradish peroxidase were employed (GE Healthcare) and
chemiluminescent detection of proteins was carried out by using
the enhanced chemiluminescence method (GE Healthcare) according
to the supplier's instructions.
2.5. RNA analysis
Total RNA was isolated from myoblasts of patients by using the
RNeasy Kit (QIAGEN, Chatsworth, CA) and reverse transcribed using
theHigh Capacity cDNAReverse TranscriptionKit (Applied Biosystems).
In order to quantify the steady state level of COL6A6 transcripts, com-
mercially available TaqMan expression assays (Applied Biosystems)
were used for the target gene (COL6A6: Hs01029204_m1 exons 12–13)
and for β-actin as a housekeeping reference gene (ACTB Endogenous
Control). Real-time PCR was performed in triplicate on the Applied
Biosystems Prism 7900HT system, using 10 ng of cDNA and default
parameters. Evaluation of COL6A6 transcript level was performed by
the comparative CT method (ΔΔCT method; Applied Biosystems User
Bulletin #2). cDNAs from control myoblasts were utilized as calibrators.
Table 1
Description of the clinical phenotypes, mutations, and immunoﬂuorescence analyses of collagen VIα1α2α3 and α6 chains' expression in muscle biopsies of collagen VI-related patients.
Abbreviations: DL, distal laxity; FC,ﬁnger's contractures; SC, skin changes (keloid formation, follicular hypercheratosis);MV, nocturnalmechanical ventilation;W,walker; NAW, never able
to walk; RI, respiratory insufﬁciency; CHD, congenital hip dislocation. R, reduced; MR, marked reduction.
Patient Phenotype Clinical features Mutation a1 a2 a3 a6
UCMD-1 UCMD Floppy at birth, CHD, NAW, DL, FC, SC,
Rl and death age 11 years
COL6A1 exon 22 c.1465delG horn;
(p.Ala489Profs*16) [32]
Absent Absent
UCMD-2 UCMD Floppy at birth, NAW, DL, FC, SC,
Rl age 10 years
COL6A1 exon 9 c.819-833del het.;
(p.Pro274_Gly278del) [33]
R at the basement membrane
of muscle ﬁbers
Traces
UCMD-3 UCMD Floppy at birth, CHD, DL, FC, SC,
walked 20 months–6 years, MV
age 11 years
COL6A1 exon8–intron 8
c.798 804 + 8del 15 het.;
(p.Pro254_Glu268 del) [34]
R at the basement membrane
of muscle ﬁbers
Traces
UCMD-4 UCMD Floppy at birth, walker 3–7 years,
DL, FC, SC, MV age 10 years
COL6A2 intron 17 c.1459-2 ANG het;
(p.Gly487-Ala495delAspfs*48);
COL6A2 intron 23 c.1771-1 GNA;
(p.Glu591-Cys605delThrfs*148) [35]
Traces Traces
UCMD-5 UCMD Floppy at birth, CHD, FC, DL, SC, aided
walker age 5 years
COL6A2 exon 28 c.2572 CNT horn;
(p.Gln858*)
R at the basement membrane
of muscle ﬁbers
Traces
UCMD-6 UCMD Floppy at birth, never able to run, DL,
FC, SC, indoor walker age 9 years,
Rl age 12 years
COL6A2 exon 12 c.1096 CNT het
(p.Arg366*); COL6A2 intron 8
c.927 + 5 GNA het;
(p.Lys318fs*6) [34]
R at the basement membrane
of muscle ﬁbers
Traces
UCMD-7 UCMD Floppy at birth, CHD, DL, FC, slow
walker at age 7 years
COL6A3 intron 16 c.6210 + 1 GNA het;
(p.Gly2053_Pro2070del)
R at the basement membrane
of muscle ﬁbers
Traces
BM-1 BM-AD Moderate weakness age 30 years, FC,
W age 60 years, mild Rl
COL6A1 intron 3 c.428 + 1 het;
(p.Tyr122-Gly143del) [38]
Normal Traces
BM-2 BM-AD Unable to run age 6, DL, FC,
MV age 49 years, W age 50 years
COL6A2 exon 6 c.802 GNA het;
(p.Gly268Ser)
Normal Traces
BM-3 BM-AD Unable to run age 18 years, FC,
W age 36 years, mild Rl.
COL6A2 intron 25 c.1970-3 CNA het;
(p.Thr656_Ala698del)
Normal MR
BM-4 BM-AD CHD, ﬁrst steps age 2.5 years, FC, DL,
W age 24, moderate Rl.
COL6A2 exon 7 c.883 GNA het;
(p.Gly295Arg)
Normal MR
BM-5 BM-AD Clubfoot, mild distal limb weakness
age 6 years, FC, W age 29, normal
respiratory function.
COL6A3 exon 11 c.4928 TNG het;
(p.Leu1643Arg)
Normal Traces
BM-6 BM-AD First steps at 2 years, never able to run,
DL, FC, W age 42, moderate Rl.
COL6A3 exon 17 c.6230 GNA het;
(p.Gly2077Asp)
Normal Traces
BM-7 BM-AD Floppy at birth, CHD, ﬁrst steps
age 2.5 years, never able to run, FC, DL,
W at age 29, moderate Rl.
COL6A3 exon 16 c.6158 GNT het;
(p.Gly2053Val)
Normal Traces
BM-8 BM-AR Floppy at birth, ﬁrst steps age 13 months,
unable to run age 6 years, FC, DL,
slow W age 30, moderate Rl.
COL6A3, exon 5 c.1393 CNT horn;
(p.Arg465*) [30]
R at the basement membrane
of several ﬁbers
MR
MM MM Early childhood weakness, severe diffuse
contractures, slow W age 21, severe Rl.
COL6A2 exon 27 c.2455 CNT horn;
(p.Gln819*) [25]
R at the basement membrane of
vessels and several muscle ﬁbers
Traces
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3.1. The collagen VI α6 chain distribution is severely affected in the skeletal
muscle of genetically characterized UCMD, BM and MM patients
We previously showed that the α6 chain is expressed in the
endomysium and perimysium of the normal human skeletal muscle,
with a more restricted pattern than the α3 chain [19]. To deﬁne the
impact of COL6A1, COL6A2 and COL6A3 gene mutations on α6 chain
distribution, we investigated muscle biopsies of genetically character-
ized UCMD, BM and MM patients (Table 1) by immunoﬂuorescence
analysis. Patients are described and grouped on the basis of their clinical
phenotype and the gene involved.
The UCMD-1 patient carried a homozygous deletion in COL6A1 exon
22 that resulted in a frameshift mutation at amino acids 504–505 in the
triple helical domain, causing a complete absence of collagen VI in skin
ﬁbroblast culture extracellular matrix [32]. The immunoﬂuorescence
analysis on muscle sections conﬁrmed the expected absence of
α1α2α3 in the endomysium and perimysium,while perlecan, amarker
of basement membranes, was normally expressed. This mutation
also compromised the α6 chain expression, which could also not be
detected (Fig. 1).
The UCMD-2 [33] (Fig. 1) andUCMD-3 [34] (Supplementary Fig. 1A)
patients, carryingheterozygousmutations in theCOL6A1 gene (Table 1),
showed a partial deﬁciency in α1α2α3 expression, characterized by
focal loss of protein in the basement membrane of muscle ﬁbers and amarked reduction of the α6 chain (Fig. 1, supplementary Fig. 1A),
which appeared to be intracellular in some interstitial ﬁbroblasts
in UCMD-2 (Fig. 1). These data suggest that the human α1 chain,
in accordance with the reported Col6a1−/− mouse model [13], is a
prerequisite for α6 chain assembly and localization in the muscle.
We also examined muscle biopsies of UCMD patients carrying
mutations in COL6A2. The UCMD-4 patient with heterocompound
mutations in the COL6A2 gene [35] showed an almost complete absence
of α1α2α3 expression; by immunolabeling, only a few perivascular
deposits of the α6 chain were detectable in the endomysium (Fig. 1).
α6 chain deposition was also dramatically reduced in muscle biopsies
of UCMD-5, carrying a COL6A2 homozygous mutation in exon 28, and
UCMD-6, with a heterozygous mutation in COL6A2 exon 12 [34],
although both mutations did not completely prevent the ECM depo-
sition of α1α2α3 chains (Supplementary Fig. 1A). A severe deﬁcien-
cy of the α6 chain was detected in the muscle biopsy of the MM
patient [25] with a homozygous mutation in COL6A2 (Fig. 1). In this
MM patient, the mutation causes instability of α1α2α3 tetramers
which do not localize correctly at the basement membranes of
muscle ﬁbers (Fig. 1). These data suggest that the α2 chain, similarly
to α1, is essential for α6 chain localization in the muscle.
We previously reported that collagen VI deﬁcient UCMD and BM
patients with mutations in the COL6A3 gene display a broad α6 chain
expression pattern in the skin [18], pointing to a compensation by the
α6 chain when the α3 chain is altered. To evaluate whether a similar
compensatory mechanism occurs in the muscle, we analyzed the
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mutation in the COL6A3 gene (UCMD-7) and in a BM patient (BM-8)
[36] with recessive mutations in the COL6A3 gene, whose skin results
were mentioned above [18]. UCMD-7 displayed a selective reduction
ofα1α2α3 chains at the basementmembrane ofmuscle ﬁbers, whereas
the α6 chain was almost completely absent (Fig. 2). The BM-8 patient
almost exclusively expresses a shorter, alternatively spliced N6–C5
isoform of the α3 chain [37], which caused a focal loss of α1α2α3
chains and a marked deﬁciency of α6-containing microﬁbrils (Fig. 2).
These data indicate that the α6 chain does not compensate for the
absence of the α3 chain in the skeletal muscle.
We investigated the distribution of the α6 chain in muscle biopsies
of seven BM patients with dominant mutations in the COL6A1, COL6A2
and COL6A3 genes (BM-1 mutation described in [38], the other
mutations are reported in the Leiden Muscular Dystrophy pages:
http://www.dmd.nl COL6A1 homepage, http://www.dmd.nl COL6A2
homepage, and http://www.dmd.nl/ COL6A3 homepage), without
evident alterations in the expression of theα1α2α3 chains. As indicated
by immunoﬂuorescence analysis, the α1α2α3 chains appeared
unaffected in all BM patients (Fig. 3 and Supplementary Fig. 1B).
Surprisingly, the expression of the α6 chain was markedly reduced
in the interstitium of all patients (Fig. 3 and Supplementary Fig. 1B),Fig. 1. Immunoﬂuorescence analysis of transversal sections of muscle biopsies from one hea
α1α2α3 heterotrimers (green) were labeled with a speciﬁc polyclonal antibody. UCMD-1 sho
the basement membranes of UCMD-2muscle ﬁbers, and present as a few aggregates in UCMD-
membrane of muscle ﬁbers of MM patients. By contrast, perlecan (red), a marker of the basem
(red)was absent inUCMD-1 andmarkedly reduced in all patients as compared to control. The la
Scale bar, 50 μm.or weakly detectable only in the perimysium of BM-2 and BM-6
patients (Fig. 3).3.2. The collagen VIα6 chain expression is normal or increased in the skeletal
muscle of patients affected by muscular dystrophies unrelated to collagen VI
We investigated theα6 chain expression pattern in muscle biopsies
of other forms of inherited muscle pathologies with primary defects
affecting different cellular compartments; in particular we analyzed
Duchennemuscular dystrophy (DMD), laminin alpha2 chain deﬁciency
(MDC1A), dysferlin deﬁciency (Miyoshi myopathy), Emery–Dreifuss
muscular dystrophy carrying a mutation in the LMNA gene (EDMD2),
Rigid Spine Syndrome (RSS) caused by mutation in SEPN1, and RSS
with mutation in FHL1. We found that the α6 chain was expressed at
normal levels in the skeletal muscles of Miyoshi myopathy, EDMD2,
SEPN1 and FHL1 patients, while it was markedly increased in the
muscles of DMD and MDC1A patients (Fig. 4). Double labeling with
anti-collagen III, used as ﬁbrosis marker, showed a strong increase of
the α6 chain in collagen III-positive areas of MDC1A muscle biopsy
(supplementary Fig. 2A), in agreement with the ECM augmentation in
ﬁbrosis [19].lthy control (CTRL), and UCMD-1, UCMD-2, UCMD-4 and MM patients. In the left panel,
wed a complete absence of α1α2α3 heterotrimers while these were strongly reduced at
4muscle interstitium (arrow).α1α2α3 heterotrimers were also reduced at the basement
ent membrane was normally expressed. Scale bar, 50 μm. In the right panel, the α6 chain
mininγ1 chain (green)was used as a basementmembranemarker. Nuclear staining, DAPI.
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matrix of BM and UCMD muscle cell cultures
To further characterize the consequences of α6 chain deﬁciency
observed in muscle sections, skeletal muscle cell cultures of BM
and UCMD patients (BM-1, BM-2, BM-6, UCMD-2, UCMD-6 and
BM-8 patients) were established and analyzed by RT-PCR, immuno-
ﬂuorescence and western blot.
By RT-PCR analysis a COL6A6 transcript up-regulation was detected
in all samples (fold change ranging from 3.297 up to 171.254).
Transcript upregulation appeared to be very strong in cultures
derived from BM-2 and BM-6 patients (Fig. 5A), without any apparent
correlation to the mutated chain or to the clinical phenotype.
By immunoﬂuorescence analysis, the α1α2α3 chain showed a
normal amount and organization in BM-2 and BM-6 cultures,
a moderate deﬁciency in BM-1 and BM-8 and a marked reduction
in UCMD-2 and UCMD-6 cultures (Fig. 5B). Intracellular retention
of α1α2α3 chains was detected in UCMD-2 patient muscle cells
(Fig. 5B, inset). These data were conﬁrmed by biochemical analysis.
Ascorbic acid-treated cell layers analyzed by western blot revealed
a normal pattern in BM-2 and BM-6 cultures, while a reduced
amount of α1–α2 and α3 chains was detected in BM-1, BM-8
and UCMD-6 cultures (Fig. 5C). UCMD-2 showed an almost normal
amount of α1α2α3 chains (Fig. 5C), possibly due to a secretion
defect, as also indicated by the intracellular retention detected by
immunoﬂuorescence analysis (Fig. 5B). The α6 chain content was
evaluated in the same muscle cell lysates. A severe reduction of
the α6 chain was observed in cell lysates of all patients compared
to controls (Fig. 5C). Immunoﬂuorescence analysis of the α6
chain was not performed, because under basal conditions the α6
chain is poorly detected in the extracellular matrix [19].
We previously reported that TGF-β1 promotes the deposition of the
α6 chain in the extracellular matrix of normal muscle cells by inducing
muscle cell trans-differentiation into a myoﬁbroblast phenotype [19].
Healthy and UCMD/BM muscle cell cultures were treated with TGF-β1
for 96 h in the presence of ascorbic acid to induce the secretion of
collagen VI. The efﬁcacy of the treatment was assessed by evaluating
the phosphorylation of its downstream effector Smad2/3 in each
culture. As expected, Smad2/3 phosphorylation on Ser 423/425 wasFig. 2. Immunoﬂuorescence analysis of transversal sections of muscle biopsies from one health
panel,α1α2α3 chains (green) appeared reduced at the basementmembrane ofmuscle ﬁbers as
UCMD-7, and to a lesser extent, of the BM-8patient. Scale bar, 50 μm. In the right panel, theα6 c
marker. Nuclear staining, DAPI. Scale bar, 30 μm.increased after TGF-β1 treatment in control as well as in patient cells
(Supplementary Fig. 2B).Moreover, TGF-β1 treatment strongly induced
transdifferentiation of muscle cells into myoﬁbroblast-like cells as
indicated by the increased expression of α-SMA (data for the UCMD-2
patient are shown in Supplementary Fig. 2C and are representative for
all patients).
The TGF-β1 treatment also induced the expression of theα6 chain in
cell cultures from all patients as well as in healthy cells; however,
a lower expression level of the protein in patients compared to controls
could still be observed by western blot analysis (Fig. 5D). The im-
munoﬂuorescence analysis showed a less abundant and organized
α6-composed extracellular matrix in UCMD/BM cultures than in con-
trols, conﬁrming the biochemical results obtained under the same ex-
perimental conditions. In addition, α6(VΙ) chain aggregates were
detected in all BM/UCMD muscle cell cultures, and in particular in
BM-1 and BM-6 derived cells (Fig. 5E). Double labeling of the α6
chain with an antibody against-Limp II, a lysosome marker, excluded a
targeting of the α6 chain into the degradative pathway (Fig. 6A).
Instead, α6 chain aggregates displayed an intense labeling with anti-
glucose-related protein 78 (Grp78), an endoplasmic reticulum (ER)
marker, suggesting a protein accumulation in the ER (Fig. 6B).
4. Discussion
Collagen VI has long been thought to be composed exclusively
of three α chains, α1, α2 and α3. The discovery of three additional
collagen VI chains in mouse (α4,α5, α6) of which two are also present
in humans (α5, α6), suggested the existence of additional assembly
forms of collagen VI [12,13,14]. Based on their structural high homology
with the α3 chain, it is conceivable that in humans the new chains may
form α1α2α5 and α1α2α6 heterotrimers.
Our study aimed to analyze the expression pattern of the α6 chain
in the skeletal muscle in UCMD, BM and MM patients to deﬁne its
involvement in the pathogenesis of collagen VI-related myopathies.
The expression of theα6 chain was reduced in skeletal muscle biopsies
of such patients, independently of their clinical phenotype, of the colla-
gen VI chainmutated, and of the effect of themutations on the assembly
and secretion of classical collagen VI heterotrimers. The strongly
reduced expression of the α6 chain in the muscle of UCMD patientsy control (CTRL), UCMD-7 and BM-8 patients, both carrying COL6A3mutations. In the left
indicated by lack of co-localizationwith perlecan labeling in discrete areas (arrows) of the
hain (red) is poorly detectable; lamininγ1 chain (green)was used as basementmembrane
Fig. 3. Immunoﬂuorescence analysis on transversal sections of muscle biopsies from one healthy control (CTRL), and BM-1, BM-2 and BM-6 patients. In the left panel, α1α2α3
chains (green) appeared normally expressed at the basement membrane and co-localized with perlecan (red ﬂuorescence). Scale bar, 50 μm. In the right panel, the α6 chain expression
(red) was strongly reduced; the laminin γ1 chain (green) indicates the basement membrane. Nuclear staining, DAPI. Scale bar, 30 μm.
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for the skin [18], and reﬂects the complex assembly mechanism of col-
lagen VImicroﬁbrils. Given the high homology of theα6 andα3 chains,
we expected a compensative role of theα6 chain in UCMDpatientswith
mutations in the COL6A3 gene, as we already detected in the skin of the
same patients [18]. On the contrary, we found a severe deﬁciency in the
muscle, indicating that the α3 chain, as well the α1 and α2 are neces-
sary for the integrity and/or normal secretion of collagen VI α6 chain.
The observation that in normal cultured muscle cells the α6 chain
does not form an independent microﬁlamentous network in the
extracellular matrix [19] strongly supports this hypothesis.Fig. 4. Immunoﬂuorescence analysis ofα6 chain expression on transversal sections ofmuscle bio
one EDMD2 (EDMD), FHL1 and SEPN1 patients. Theα6 chain (red) appeared normally expresse
MDC1A patients. The laminin γ1 chain (green) was used as a basement membrane marker. NuFurthermore, we found that the α6 chain did not substitute and
compensate for α3 deﬁciency in the skeletal muscle, in agreement
with a recent study on Col6a3(+/d16) mice [39]. The absence of
compensatory mechanisms in the muscle of patients with mutations
in COL6A3 could depend on the different distribution pattern of α6
chain with respect to the α3. In the skin of COL6A3 patients, the α6
chain compensated for the absence of the α3 in the papillary dermis,
where α3 and α6 chains are both expressed. In the skeletal muscle,
while α3 is clearly part of the basement membrane of muscle ﬁbers,
the α6 chain is only interstitial and absent in the basement membrane.
Considering that COL6A3 patients studied in this paper showed apsies fromonehealthy control (CTRL), DMD,MDC1A, oneMiyoshimyopathy (MiyoshiM),
d in EDMD, andMiyoshimyopathy FHL1 and SEPN1 patients and upregulated in DMD and
clear staining, DAPI. Scale bar, 20 μm.
Fig. 5. (A) Relative quantiﬁcation of the endogenous COL6A6mRNA in twoUCMDand four BMpatients. TheCOL6A6 gene is up-regulated in all patients (fold change ranging from3.297 up to
171.254). The COL6A6mRNA level in control myoblasts (CTRL) is set to 1. The values reported in the graph are the average between two independent experiments. (B) Immunoﬂuorescence
analysis of the α1α2α3 heterotrimer in control, four BM and two UCMD-conﬂuent muscular ﬁbroblasts after 4 days of L-ascorbic acid treatment. The α1α2α3 chains appeared normally
assembled and secreted in BM-2 and BM-6 cultures, while they were reduced in BM-1 and in all UCMD patient cultures. A particularly strong intracellular retention was detected in the
UCMD-2 patient (inset). Nuclear staining, DAPI. Scale bar: 20 μm. (C) Western blot analysis of cell layer from muscle cell cultures derived from two unaffected donors (CTRL), and BM-1,
BM-2, BM-6, UCMD-2, UCMD-6 and BM-8 patients. Cells were treated for 4 days with L-ascorbic acid post-conﬂuence, scraped and samples were separated on a 4–20% polyacrylamide
gel under reducing conditions. The α1α2α3 heterotrimer and the α6 chain were evaluated by speciﬁc antibodies. The loading control was performed using a GAPDH antibody. Lower
numbers indicate α6 chain/GAPDH ratio by densitometry. (D) Western blot analysis of cell layers from two unaffected donors (CTRL), and BM-1, BM-2, BM-6, UCMD-2, UCMD-6 and
BM-8 patients treated for 4 days with L-ascorbic acid and 10 ng/ml TGF-β1. Cells were scraped and samples were separated on a 4–20% polyacrylamide gel under reducing conditions.
Theα1α2α3heterotrimer and theα6 chainwere evaluated by speciﬁc antibodies. GAPDHwasused as a loadingmarker. Lower numbers indicate theα6 chain/GAPDH ratio by densitometry.
(E) Immunoﬂuorescence analysis of theα6 chain in control (CTRL), BM-1, BM-2, BM-6, UCMD-2, UCMD-6 andBM-8patientmuscle cell cultures treated for 4 dayswith TGF-β1 and L-ascorbic
acid. All patients’ cells displayed a strongly reduced amount of theα6 chain, with a signiﬁcant intracellular retention in BM-1 and BM-6muscle cells. Nuclear staining, DAPI. Scale bar, 10 μm.
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the absence of compensatory mechanisms could be attributed to
the fact that the α6 chain is not part of this speciﬁc structure. The
study of patients with the complete absence of collagen VI caused
by homozygous mutations in COL6A3 or models lacking α3 chains
could be helpful for a better understanding of the role of the α3
chain in the α6 assembly. On the other hand, we cannot exclude
that the α6 chain can be part of tissue speciﬁc alternative collagen
VI assemblies [16]. However, skin ﬁbroblasts produce the α3 butnot the α6 chain (unpublished personal data), thus today, a cell
model for biochemical investigation is lacking.
The absence of the α6 chain in the muscle of autosomal dominant
BM patients with mutations which do not affect the assembly and
deposition of theα1α2α3 chains is surprising. Under a basal condition,
the protein was scarcely detectable by western blot despite that
the transcript was upregulated in all patients compared to controls.
The expression of collagen VI chains is highly regulated at different
levels such as gene transcription, processing of encoding RNAs,
Fig. 6.Confocal analysis of amuscle cell culture derived frompatient after treatmentwith TGF-β1. Double labelingof theα6 chain (red)with Limp II (lysosomemarker, inA) andGrp78 (ER
marker, in B) excluded lysosomal localization but demonstrated accumulation of protein aggregates in the endoplasmic reticulum. Nuclear staining, DAPI. Scale bar, 20 μm.
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and the impairment of the efﬁciency of each step may affect protein
assembly and secretion. Interestingly, TGF-β1 treatment induced the
α6 chain expression in patients as well as in control cells; however,
in patients with collagen VI-related myopathies, the α6 chain failed
to develop a network-like matrix outside the cell and accumulated
as aggregates in the ER. This result suggests that the protein retention
maybe due to a defect in the post-translational machinery or in the su-
pramolecular protein assembly. Retention of collagenVI in the secretory
pathway was recently detected in mouse bronchiolar epithelial cells,
where the absence of the phospholipid-binding protein annexin A2
leads to collagen VI retention within the Golgi compartment [40].
However, we cannot exclude that altered mechanisms downstream of
the collagen VI deﬁciency may interfere with the correct α6 chain
production selectively in the skeletal muscle, the most affected tissue
in collagen VI-related patients. In a paper in collaboration with other
groups we demonstrated that Col6a1 knockout mice and BM–UCMD
patient muscles display an impairment of the autophagic mechanism,
which leads to inadequate removal of defective mitochondria and
spontaneous apoptosis [41]. It has been reported that autophagy is
involved in collagen turnover [42], and that the impairment of
autophagy induces the accumulation of procollagen aggregates in
the endoplasmic reticulum [43].
Diagnosis of collagen VI related myopathies is complex and a
deﬁnite assignment of collagen VI genes requires molecular genetic
testing currently available in only a few medical centers.
The immunohistochemical and western blot analysis of collagen VI
in muscle biopsies and skin ﬁbroblasts may be helpful for the diagnosis
of UCMD [44], BM with recessive mutations [24] and MM [25], since it
reveals a reduced and/or altered expression pattern. However, in sever-
al BMpatientswith dominantmutations, collagenVI immunolabeling is
indistinguishable from the normal pattern both in skeletal muscle
biopsies and cultured skin ﬁbroblasts [29]. Moreover, the report of
collagen VI deﬁciency in muscle biopsies of patients without mutations
in collagen VI genes [45] and with UCMD/BM overlapping clinical
featuresweakens the diagnostic signiﬁcance of collagenVI protein anal-
ysis. So far, speciﬁc changes inmuscle biopsies of dominant BMpatients
have never been reported. BM [46] andMM [25] patients may display a
secondary reduction of laminin β1 labeling, however this ﬁnding is not
speciﬁc to collagenVI relatedmyopathies since it has also been reportedin Emery–Dreifuss muscular dystrophy [47]. The normal level, or even
the upregulation, of the α6 chain in muscular dystrophies not related
to collagen VI, and in forms with BM overlapping phenotypes [48]
indicates that the altered expression of theα6 chain it is not a common
mechanism, related to the dystrophic process per se. This further
supports the assertion that in the principal contractured phenotypes
mimicking collagen VI disorders the α6 chain is not affected.
Fibrosis is the most conspicuous pathological alteration in dystro-
phic muscle. It consists in a non-reversible remodeling of the ECM,
which signiﬁcantly contribute to muscle dysfunction. We previously
reported that the α6 chain expression is induced by the proﬁbrotic
factor TGF-β1, and that it is strongly up-regulated in DMD muscle
ﬁbrosis [19]. Here we show that the α6 chain is up-regulated in
MDC1A, another form of muscular dystrophy with prominent ﬁbrosis
and involvement of TGF-β1 signaling [49].
5. Conclusions
The discovery of additional collagen VI chains in the human skeletal
muscle added new complexity to collagen VI biology, as their roles
in development, tissue homeostasis and pathogenesis of inherited
diseases are completely unknown. The defect of α6 chain we detected
in collagen VI-related myopathies points to a contribution to the
pathogenesis of collagen VI-related disorders.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.05.033.
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